Descripción de la empresa
Myriad Genetics, Inc. operates as a specialized entity within the healthcare sector, specifically focusing on the diagnostics and research industry by developing molecular tests for oncology, women's health, and pharmacogenomics. The company's portfolio includes specific offerings such as the MyRisk Hereditary Cancer test, which utilizes DNA sequencing to identify hereditary cancers, alongside other diagnostic tools for BRA analysis. This molecular diagnostics and precision medicine company maintains a workforce of 2,700 employees, reflecting a significant operational scale within its niche. The company's current market capitalization stands at $443.23 million, while its trailing twelve-month revenue totals $557.00 million, indicating a mid-cap enterprise that has secured a substantial market position despite recent contraction in top-line growth. These valuation and revenue figures suggest a company that holds a notable footprint in the genetic testing landscape but faces headwinds that have impacted its overall economic size relative to its historical peaks.
Salud financiera
The company reported annual revenue of $557.00 million over the trailing twelve months, yet this revenue generated a net income loss of $230,000,000 and an EBITDA of $-111,900,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses and tax impacts have overwhelmed earnings before interest and taxes, resulting in a bottom-line deficit. Free cash flow for the period was $-46,062,500, which indicates that the company is currently consuming cash rather than generating liquidity, thereby limiting its immediate financial flexibility for organic expansion or capital return initiatives. The gross margin stands at 68.1%, suggesting that the cost of goods sold is relatively low compared to revenue, yet the operating margin of -21.4% and the profit margin of -41.3% demonstrate that high fixed costs or administrative overhead are severely eroding profitability at the operational and net levels. The company holds $150.70 million in cash while debt figures are not applicable in the standard reporting provided, though the debt-to-equity ratio is listed as 32.84, a metric that requires careful interpretation given the negative earnings context. The current ratio is 2.67, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer against near-term obligations. Return on equity is -23.5% and return on assets is -7.6%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns, a situation typical of turnaround scenarios or periods of aggressive investment without immediate payoff.
Evaluación de valoración
The valuation metrics present a complex picture, with a forward P/E ratio of 28.23 while the trailing P/E ratio is not applicable due to the company's negative earnings. The discrepancy between a forward multiple that suggests future profitability expectations and a trailing P/E that cannot be calculated implies that the market is pricing in a significant recovery in earnings trajectory rather than current operational performance. The price-to-book ratio is 1.20, indicating that the market values the company at a slight premium over its book value, a multiple that often persists in biotech and healthcare firms with intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics further complicate the analysis, as the price-to-sales ratio sits at 0.80 and the EV/EBITDA is -2.61, suggesting that the company is trading below one dollar of sales and possesses negative enterprise value multiples relative to earnings, which is common for loss-making companies. The stock has traded between a 52-week low of $3.76 and a 52-week high of $8.59, meaning the current price sits within this historical volatility range but reflects the uncertainty surrounding its path to profitability. The beta value is 1.64, which signifies that the stock is significantly more volatile than the broader market, amplifying price swings in both upward and downward directions relative to the S&P 500 index.
Growth & Income
Revenue growth year-over-year stands at -20.8%, while earnings growth is not applicable due to the negative net income position. The fact that revenue is contracting while earnings are negative implies that the company is struggling to maintain its top line, which naturally prevents any meaningful earnings growth in the current fiscal period. As a non-dividend payer, the company offers a dividend yield of 0.0% and maintains a payout ratio of 0.0%, indicating that the firm retains all available cash to fund operations and potentially address its losses rather than distributing income to shareholders. This reinvestment strategy is typical for companies in distress or during a pivot, where capital is directed toward operational restructuring rather than shareholder returns. The overall growth and income profile is characterized by a contraction in sales, a complete absence of earnings generation, and no distribution of dividends, highlighting a firm that prioritizes survival and potential future profitability over immediate financial returns or income generation for its investors.